Cargando…
A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection
Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are currently the two leading causes of death among infectious diseases. As we progress towards a “new normal”, more information is required regarding post-COVID-19 syndromes. We present a case of latent tuberculosis reactivation 3 months aft...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222568/ https://www.ncbi.nlm.nih.gov/pubmed/35735758 http://dx.doi.org/10.3390/idr14030048 |
_version_ | 1784732897674002432 |
---|---|
author | Leonso, Ana-Alicia Brown, Kyle Prol, Raquel Rawat, Saumya Khunger, Arjun Bromberg, Romina |
author_facet | Leonso, Ana-Alicia Brown, Kyle Prol, Raquel Rawat, Saumya Khunger, Arjun Bromberg, Romina |
author_sort | Leonso, Ana-Alicia |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are currently the two leading causes of death among infectious diseases. As we progress towards a “new normal”, more information is required regarding post-COVID-19 syndromes. We present a case of latent tuberculosis reactivation 3 months after a successful inpatient treatment of COVID-19. A 74-year-old female from the Philippines presented with a new left mid-lung infiltrate with worsening shortness of breath and lethargy for one week prior to admission. The clinical course of the patient deteriorated despite broad-spectrum antibiotics, diuretics, and high-dose steroid therapy requiring intubation and mechanical ventilation. Her sputum culture yielded the microbiological diagnosis of TB. Anti-tubercular medications were started and the patient had a favorable clinical outcome. Our case demonstrates that immunosuppression secondary to COVID-19 and its treatments may promote the development of an active TB infection from a latent infection. It is important to be aware of this potential increase in risk during and after a COVID-19 treatment. This is especially important in high-risk populations to ensure an early diagnosis and prompt management as well as to reduce transmission. |
format | Online Article Text |
id | pubmed-9222568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92225682022-06-24 A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection Leonso, Ana-Alicia Brown, Kyle Prol, Raquel Rawat, Saumya Khunger, Arjun Bromberg, Romina Infect Dis Rep Case Report Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are currently the two leading causes of death among infectious diseases. As we progress towards a “new normal”, more information is required regarding post-COVID-19 syndromes. We present a case of latent tuberculosis reactivation 3 months after a successful inpatient treatment of COVID-19. A 74-year-old female from the Philippines presented with a new left mid-lung infiltrate with worsening shortness of breath and lethargy for one week prior to admission. The clinical course of the patient deteriorated despite broad-spectrum antibiotics, diuretics, and high-dose steroid therapy requiring intubation and mechanical ventilation. Her sputum culture yielded the microbiological diagnosis of TB. Anti-tubercular medications were started and the patient had a favorable clinical outcome. Our case demonstrates that immunosuppression secondary to COVID-19 and its treatments may promote the development of an active TB infection from a latent infection. It is important to be aware of this potential increase in risk during and after a COVID-19 treatment. This is especially important in high-risk populations to ensure an early diagnosis and prompt management as well as to reduce transmission. MDPI 2022-06-12 /pmc/articles/PMC9222568/ /pubmed/35735758 http://dx.doi.org/10.3390/idr14030048 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Leonso, Ana-Alicia Brown, Kyle Prol, Raquel Rawat, Saumya Khunger, Arjun Bromberg, Romina A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection |
title | A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection |
title_full | A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection |
title_fullStr | A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection |
title_full_unstemmed | A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection |
title_short | A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection |
title_sort | rare case of latent tuberculosis reactivation secondary to a covid-19 infection |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222568/ https://www.ncbi.nlm.nih.gov/pubmed/35735758 http://dx.doi.org/10.3390/idr14030048 |
work_keys_str_mv | AT leonsoanaalicia ararecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT brownkyle ararecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT prolraquel ararecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT rawatsaumya ararecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT khungerarjun ararecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT brombergromina ararecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT leonsoanaalicia rarecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT brownkyle rarecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT prolraquel rarecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT rawatsaumya rarecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT khungerarjun rarecaseoflatenttuberculosisreactivationsecondarytoacovid19infection AT brombergromina rarecaseoflatenttuberculosisreactivationsecondarytoacovid19infection |